IT’S NOT THE NICOTINE, IT’S THE SMOKE. DOCTORS ARE STILL GETTING THIS WRONG

That is not a footnote. It is the heart of the problem.

As physicians, we prescribe off-label all the time. A drug may be approved for one condition but used for another when evidence, experience and patient need support it. Off-label prescribing is not automatically reckless. Sometimes it is thoughtful medicine.

But this is different.

Off-label prescribing starts with an FDA-approved drug. There is a label to depart from. There is a manufacturer that submitted data. There is a defined formulation, a known dose, a manufacturing process, adverse-event reporting, facility inspection and a regulatory record.

With these compounded peptides, there is no approved drug to prescribe off-label. There is no FDA-approved label. There is no accepted indication, dose, formulation or risk profile. There is no ordinary drug-approval record being used creatively at the bedside.

There is simply a substance people want to use — and a market eager to sell it.

That is not enough.

The modern FDA standard rests on a simple idea: before a substance is treated as medicine, someone must show that it is safe and effective for a defined use, in a defined formulation, at a defined dose, made under defined conditions. That standard is not bureaucratic theater. It is the reason patients can generally trust that a prescription bottle contains what it says, in the strength promised, made under inspected conditions, with risks that were at least studied before the product reached the public.

Drug developers spend years — often more than a decade — moving a product from laboratory concept to human testing to FDA review. They must define endpoints, monitor adverse events, manufacture under quality standards, submit data and undergo inspection. We can argue about whether that system is too slow, too expensive or too risk-averse. Sometimes it is.

But the answer cannot be to create a shadow pathway for fashionable compounds simply because they are popular in wellness clinics and on podcasts.

Compounding has a legitimate role in medicine. It allows pharmacists to meet specific needs for individual patients. A child may need a liquid version of a medication. A patient may need a dye, preservative or allergen removed. A dosage form may need to be adjusted. During severe drug shortages, the FDA may also allow temporary compounding when the public need is urgent and the risk-benefit calculation favors access.

That is very different from using compounding to normalize unapproved drugs for broad commercial use.

The FDA’s own materials make clear that bulk substances used in compounding are supposed to meet defined legal and regulatory criteria, including appearing on appropriate bulk-substance lists or, in some circumstances, being connected to drug shortages or clinical need. Yet the advisory committee has now moved in the opposite direction of the agency’s traditional evidentiary caution. Recent reporting described FDA scientists warning about the limited evidence for these products even as advisers voted to ease restrictions on multiple peptides.

That should alarm anyone who cares about the FDA’s credibility.

Advisory committees are useful when they bring independent expertise to hard scientific questions. But expertise and financial exposure are not the same thing. If panelists stand to benefit from expanded peptide compounding, the public has a right to know exactly what those ties are, whether waivers were issued, who approved them and why less-conflicted experts could not serve.

The answer cannot be: trust us.

Trust is precisely what is at stake.

The problem is not that peptides are inherently worthless. Some may eventually prove useful. Medical history is full of therapies that began as intriguing biological ideas. But promising hypotheses do not become medicine because influencers promote them, patients request them or politically favored advisers bless them.

They become medicine when evidence catches up with enthusiasm.

That is why this vote matters beyond BPC-157, KPV, TB-500 and MOTS-c. The danger is not only that the FDA may make the wrong decision on several peptides. The larger danger is that the agency may create a model for bypassing drug approval whenever patient demand, commercial enthusiasm and political pressure all point in the same direction.

For physicians, that creates a dangerous ambiguity at the bedside. If a compounded peptide becomes widely available after an FDA advisory vote, patients may assume it has been meaningfully vetted. They may hear “FDA panel” and think “FDA approved.” They may assume a pharmacy-compounded product has the same evidentiary foundation as an approved medication.

That ambiguity also creates an opening for abuse. A careful physician may tell a patient that evidence is limited and risks remain uncertain. But an unscrupulous clinic owner can turn the same product into a sales pitch: wound healing, inflammation relief, muscle recovery, longevity, vitality — all wrapped in the aura of an “FDA-advised” compounded treatment, without the proof a drug sponsor would have to provide.

It does not have that proof.

And we physicians should not be put in the position of explaining why a product that looks medically legitimized has not actually been tested like a medicine.

The FDA is not required to follow this advisory committee. It can accept the recommendation, reject it or demand more evidence. When the agency’s own staff review points one way and a narrowly divided, conflict-clouded advisory vote points another, the FDA should not treat the vote as political permission to lower its standards.

Kennedy and his supporters often say they want transparency and accountability in medicine. This is a chance to prove it.

Before FDA acts, HHS and FDA should publicly disclose the conflict reviews and any waivers for voting members. FDA guidance itself recognizes that advisory-committee financial interests and waivers implicate public transparency and statutory conflict rules. The agency should explain how it weighs staff findings against advisory-committee recommendations. It should clarify whether compounded access to unapproved peptides is being treated as an exceptional case or as a template for other products that have not met ordinary evidentiary standards.

Most of all, the FDA should say plainly that patient demand does not replace evidence. Commercial enthusiasm does not replace trials. Influencer medicine does not replace pharmacology. And advisory committees do not exist to launder unapproved drugs into medical legitimacy.

This is not an argument against peptide research. It is an argument for doing the research properly.

If these peptides have therapeutic value, sponsors should study them in rigorous human trials. They should define indications, doses, formulations, manufacturing standards, safety monitoring and endpoints. They should publish results. They should submit data. They should meet the same standards expected of everyone else.

That may be slower than compounding. It may be less satisfying to patients who want access now and businesses that want a market now.

But that is the difference between medicine and marketing.

AMERICA’S DEADLIEST PRODUCTS ARE LEGAL. THE SAFER ONES ARE IN COURT

The FDA’s peptide decision will show whether the agency still believes in its own evidentiary framework when politics, patient demand and commercial interest push against it.

The agency should follow the evidence — especially when the evidence is what its own staff already provided.

Arie Blitz, M.D., M.B.A., F.A.C.C., is a retired cardiothoracic surgeon and independent writer who writes on biotechnology regulation, medical ethics, and health policy. He previously held academic and clinical leadership roles in cardiac surgery, heart transplantation, and mechanical circulatory support.